Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Exelixis
Neonc Technologies, Inc.
Bristol-Myers Squibb
Aulos Bioscience, Inc.
ImmunityBio, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Mayo Clinic
University of Pittsburgh
University of Pittsburgh
Nanobiotix
ImmuneSensor Therapeutics Inc.
7 Hills Pharma, LLC
Vyriad, Inc.
Incyte Corporation
Sarcoma Oncology Research Center, LLC
Eli Lilly and Company
Molecular Templates, Inc.
Yale University
Biomica Ltd.
University Hospital, Ghent
Rutgers, The State University of New Jersey
HUYABIO International, LLC.
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
Duke University
Genocea Biosciences, Inc.
Five Prime Therapeutics, Inc.
Bristol-Myers Squibb
Sheba Medical Center
MultiVir, Inc.
Western Regional Medical Center
Bristol-Myers Squibb